Rossari Biotech Announces Q4 & FY25 Results: Revenue at Rs. 579.6 Cr, EBITDA at Rs. 69.5 Cr, PAT at Rs. 34.4 Cr

Rossari Biotech Limited, a Specialty-Chemicals manufacturer, has announced its financial results for the quarter ended March 31, 2025. The company reported a 22.6% increase in revenue from operations to Rs. 579.6 crore compared to Q4 FY24. EBITDA improved by 9.3% to Rs. 69.5 crore, but the EBITDA margin decreased to 12.0% from 13.5%. PAT increased by 0.9% to Rs. 34.4 crore, and EPS (Diluted) stood at Rs. 6.21. For the full year, revenue from operations stood at Rs. 2,080.3 crore, up 13.7% from FY24. EBITDA increased by 6.1% to Rs. 265.1 crore, but the EBITDA margin decreased to 12.7%. PAT was higher by 4.4% to Rs. 136.4 crore, and EPS (Diluted) stood at Rs. 24.63. The company is optimistic about the growth of its HPPC, TSC, and AHN segments and is investing in capacity expansion to support this growth.